Anupam Rasayan India Limited announces an acquisition

Yes. The change of control triggered a mandatory Open Offer under Regulations 3(1) and 4 of the SEBI (SAST) Regulations.

• Underlying acquisition: Anupam Rasayan acquired a controlling 43.3% stake in Bliss GVS Pharma for approximately Rs 1,369 Crores. ^[1]
• Open Offer: The offer was made for up to 26% of Bliss GVS Pharma at Rs 299 per share. ^[1]
• Maximum contingent liability: Assuming full acceptance, the Open Offer consideration was Rs 829.03 Crores — the disclosed maximum consideration. ^[2]
• Indicative maximum aggregate cash outlay: Approximately Rs 2,198.03 Crores, derived from Rs 1,369 Crores for the underlying acquisition plus Rs 829.03 Crores for the maximum Open Offer acceptance. This is an arithmetic aggregation of the two disclosed amounts, not a separately reported transaction figure.

The control trigger was subsequently evidenced by Anupam Rasayan and its PAC collectively holding 50.07% of Bliss GVS Pharma and being designated as promoters effective 28 September 2026. ^[3] The Rs 829.03 Crores should therefore be read as the maximum potential Open Offer liability, rather than necessarily the final cash payment; the actual amount depends on the number of shares validly tendered and accepted.

The acquisition is not reported as being funded by internal accruals plus debt. The reported structure is a Rs 300 Crore term loan, with approximately Rs 1,450 Crores raised from financial investors through non-controlling, non-voting instruments ^[4].

• Debt: Rs 300 Crores, or approximately 17.14% of the reported Rs 1,750 Crore funding package.
• Internal accruals: Not separately identified in the completion-related disclosure. The balance is described as external investor funding, not internal accruals.
• Investor instruments: Approximately Rs 1,450 Crores, or 82.86% of that reported package. These percentages are derived from the cited amounts ^[4].

The earlier transaction description was based on a Rs 1,369 Crore acquisition consideration, funded by the same Rs 300 Crore term loan and the balance through a non-controlling, non-voting equity instrument ^[5]. The difference between the Rs 1,369 Crore transaction figure and the later Rs 1,450 Crore investor-funding figure likely reflects different transaction scopes or subsequent funding requirements; they should not be mechanically combined.

Net debt-to-equity: A post-completion net debt-to-equity ratio has not been reported in the cited material. It cannot be calculated reliably from the funding split alone because it requires Anupam Rasayan’s pre-deal net debt, cash deployed, equity base, and the accounting treatment of the non-controlling, non-voting instruments. The defensible conclusion is that the acquisition adds Rs 300 Crores of reported term debt, while most of the stated funding comes from investor instruments rather than internal accruals; the precise post-deal net debt-to-equity ratio remains undisclosed.

_Scope note: this comparison also included Bliss GVS Pharma (BLISSGVS), which the answer above does not cover. Ask about any of them for a full side-by-side._

The filing’s rationale is for a vertical, end-to-end life-sciences platform, rather than a clearly specified plan to merge Bliss’s plants with Anupam’s chemical units. The expected synergies are:

• KSM-to-finished-dose integration: Anupam’s advanced chemistry and key-starting-material capabilities would be combined with Bliss’s formulation capabilities across suppositories, pessaries, tablets, capsules, syrups, injectables, creams and ointments. This could improve supply-chain coordination and allow the group to capture more value across the pharmaceutical chain. ^[6]
• Broader product development: Anupam’s chemistry platform and Bliss’s niche dosage-form expertise are expected to support expanded product offerings across therapeutic segments, rather than limiting Anupam to intermediates and custom synthesis. ^[6]
• Accelerated R&D and innovation: The filing specifically identifies “accelerated innovation” as a potential benefit. In practical terms, this implies combining Anupam’s chemistry capabilities with Bliss’s formulation and dosage-form development expertise to develop or commercialise products more efficiently. The filing does not identify specific molecules, joint R&D programmes or approval timelines. ^[6]
• Operational scaling of Bliss: Management separately described the use of Anupam’s technology and marketing capabilities to scale Bliss, analogous to the approach used with Tanfac. The stated opportunity includes improving Bliss’s low capacity utilisation and expanding its presence in Europe, the US and India. ^[7]
• Market and customer leverage: The combined platform is expected to offer customers a wider proposition—from chemical building blocks to finished formulations—while strengthening customer engagement and access to regulated markets. ^[6]

Important limitation: the rationale does not specify hard operational measures such as shared manufacturing lines, named facilities to be integrated, quantified procurement savings, common R&D budgets or a defined technology-transfer programme. Therefore, the immediate synergy case is strategic and capability-led; its financial realisation will depend on execution, product approvals, customer adoption and the ability to raise Bliss’s utilisation.